The M1 subset, which is involved in antitumor immunity and anti-angiogenesis and M2 CD163+ subset, have the opposing roles of enhancing immunosuppression and angiogenesis in tumor progression, and may be considered the two extremes of a large spectrum that can exert anti- and pro-tumoral activities [30,31]. This evidence concerns the gene CD163 and neoplasm.